Neuraxpharm selected for prestigious pilot program to supply medical cannabis in France

Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), today announces that its affiliate Neuraxpharm France has been selected as one of winners for the participation in a pilot program for the medical use of cannabis issued by The National Agency for the Safety of Medicines and Health Products (ANSM), together with Panaxia Labs, Israel’s largest medical cannabis manufacturer.

Read more….

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...